| Project/Area Number |
23592022
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Aichi Cancer Center Research Institute |
|---|
Principal Investigator |
UEMURA Yasushi 愛知県がんセンター(研究所), 腫瘍免疫学部, 主任研究員 (40364781)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KUZUSHIMA Kiyotaka 愛知県がんセンター研究所, 部長 (30311442)
SENJU Satoru 熊本大学, 医学薬学研究部, 准教授 (50274709)
OKAMURA Ayako 愛知県がんセンター研究所, 研究員 (10546948)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 外科 / 膵臓癌 / 免疫 / 癌 / がん / NKT細胞 / 樹状細胞 / 免疫療法 / ナチュラルキラーT細胞 |
|---|
| Research Abstract |
Currently, cancer antigen-derived T cell epitope peptide vaccines are under development and clinical trials have already been performed. Unfortunately, outcomes have been disappointing. To address these issues, we focused on invariant NKT cells that recognize alpha-GalCer presented by CD1d. We established iNKT cell-based anti-tumor effector T cells that express a tumor reactive T cell receptor (TCR). The TCR-transduced CD4-CD8- (DN) iNKT cells were excellent for tumor antigen-specific cytotoxicity. In contrast, the TCR-transduced CD4+CD8- (CD4) iNKT cells acted as a cellular adjuvant inducing robust IL-12p70 production in alpha-GalCer-loaded dendritic cells. Tumor-reactive TCR-expressing iNKT cell that exert cytotoxic activity and adjuvant activity may be a powerful tool for cancer immunotherapy.
|
